Skip to main content
RT @KDAO2011: OP0285 Voclosoporin effective in #lupusNephritis from AURA-LV and AURORA1 to achieve EULAR/ERA nephritis t

TheDaoIndex KDAO2011

4 years 3 months ago
OP0285 Voclosoporin effective in #lupusNephritis from AURA-LV and AURORA1 to achieve EULAR/ERA nephritis targets (proteinuria < 0.7 mg/mg and pred < 7.5 mg/d) at 1 year @AuriniaPharma #EULAR2022 @rheumnow https://t.co/0GoCgP98F2
RT @drdavidliew: MACE in JAKi vs TNFi: did spontaneous reporting pharmacovigilance pick it?

Vigibase: MACE (really MI)

David Liew drdavidliew

4 years 3 months ago
MACE in JAKi vs TNFi: did spontaneous reporting pharmacovigilance pick it? Vigibase: MACE (really MI) & VTE signals there before the scare Always chance regulatory warnings cause stimulated reporting but signal here was clear before RCT-driven alerts OP0268 #EULAR2022 @RheumNow https://t.co/hTJD1gMgyy
Update in Spondyloarthritis
Video: Further Considerations of the ORAL Surveillance Study

Further Considerations of ORAL Surveillance Study - this w

Dr. John Cush RheumNow

4 years 3 months ago
Video: Further Considerations of the ORAL Surveillance Study Further Considerations of ORAL Surveillance Study - this week there are new analyses and sub-analyses that further explain findings and who this data applies to. #EULAR2022 https://t.co/a2XKthtMbs https://t.co/kYNS1AesHT
Another Take on the 2022 EULAR RA Treatment Guidelines
  • Dr. Peter Nash
RT @synovialjoints: Real world study of over 6500 patients from a French Health Insurance database by Pina Vegas et al s

Dr. Antoni Chan synovialjoints

4 years 3 months ago
Real world study of over 6500 patients from a French Health Insurance database by Pina Vegas et al showed higher persistence of IL17i than TNFi for PsA and PsO. IL17i had better persistence than IL12/23 for PsA and no difference for PsO over 3 years #EULAR2022 @RheumNow POS0075 https://t.co/hBI8tgb5Jb
WATCH: New 2022 ASAS/EULAR Recommendations on the Management of AxSpA

Dr. Sophia Ramiro (Leiden University Medical Cent

Dr. John Cush RheumNow

4 years 3 months ago
WATCH: New 2022 ASAS/EULAR Recommendations on the Management of AxSpA Dr. Sophia Ramiro (Leiden University Medical Center) presents an overview of the new Spondyloarthritis treatment guidelines from ASAS/EULAR Task Force. #EULAR2022 https://t.co/AiCNQPm6KB https://t.co/kn4rmcbZrH
A full day at EULAR with oral and poster presentations of abstracts in the morning and a plethora of scientific (review) sessions in the afternoon. The latter covering topics like sarcoidosis, Still’s disease, fibromyalgia, back pain, sarcopenia, APS, IgG4 and imaging in vasculitis.
RT @uptoTate: What is "backfill" on MRI? Answer: joint space lesions with a calcified matrix resembling new bone formati

Dr. Rachel Tate uptoTate

4 years 3 months ago
What is "backfill" on MRI? Answer: joint space lesions with a calcified matrix resembling new bone formation found in axSpA. #EULAR2022 POS0149 argues for a standardization of this nomenclature. @RheumNow https://t.co/ifrowQnRcn
RT @uptoTate: To contrast or not to contrast (in RA hand MRI?) POS0718 from #EULAR2022 showed good correlation between c

Dr. Rachel Tate uptoTate

4 years 3 months ago
To contrast or not to contrast (in RA hand MRI?) POS0718 from #EULAR2022 showed good correlation between contrast/non-contrast imaging in synovitis, less so in tenosynovitis however. https://t.co/xL4XcRlIog @RheumNow https://t.co/0cTep6MHLu
RT @synovialjoints: The expanding spectrum of Systemic Autoinflammatory Disease (SAID) by Marco Gattorno using a combina

Dr. Antoni Chan synovialjoints

4 years 3 months ago
The expanding spectrum of Systemic Autoinflammatory Disease (SAID) by Marco Gattorno using a combination of clinical assessment, genetic testing and imaging to define the phenotype of SAID #EULAR2022 @RheumNow https://t.co/TGYmfExHxD
EULAR Congress 2022 highlighted several posters on pregnancy, an important subject as most rheumatic diseases afflicts women during their childbearing years. I wanted to share with you the ones that caught my eye because they can potentially impact medical practice.
Infiltrating macrophages expressing IL-6 and GM-CSF may drive the subacromial bursitis often seen in polymyalgia rheumatica, according to new research (abstract OP0015) presented on the first day of EULAR 2022 in Copenhagen.
Translating targeted therapy from bench to bedside has been more problematic in SLE than other autoimmune diseases, with many theoretically well-founded agents appearing to have failed in clinical trials as a result of inefficacy, problem with trial design and/or safety issues. 
×